Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
WST · NYSE · United States · Surgical & Medical Instruments & Apparatus
In shortWEST PHARMACEUTICAL SERVICES INC is profitable, generates cash and holds more cash than debt, with revenue growing (+6.3% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 19.0% | 80/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 16.1% | 84/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 16.9% | 84/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 13.8% | 92/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.02× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.06× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 1169.80× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 9.34 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 15.3% | 81/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.95× | 81/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 13.6% | 61/100 |
| Operating margin volatility | 3.4% | 79/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 2.1% | 28/100 |
|---|---|---|
| EPS growth, 3-year average | -4.2% | 4/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 2,832 | 2,887 | 2,950 | 2,893 | 3,074 |
| Cost of revenue | 1,656 | 1,751 | 1,821 | 1,895 | 1,970 |
| Gross profit | 1,176 | 1,136 | 1,129 | 999 | 1,104 |
| Research & development | 53 | 59 | 68 | 69 | 74 |
| Selling, general & admin | 363 | 317 | 353 | 339 | 394 |
| Operating income | 752 | 734 | 676 | 570 | 585 |
| Interest expense | 8.2 | 7.9 | 9 | 3 | 0.5 |
| Pre-tax income | 749 | 680 | 698 | 586 | 601 |
| Income tax | 107 | 115 | 122 | 108 | 122 |
| Net income | 662 | 586 | 593 | 493 | 494 |
| Diluted EPS | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| Diluted shares (millions) | 76 | 76 | 75 | 74 | 73 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
9.34 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 23, 2026